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HObjectives: Our objective was to determine the feasibility and early to medium-term outcome of stenting the
patent ductus arteriosus at the time of radiofrequency valvotomy in the subgroup of patients with pulmonary
atresia with intact ventricular septum and intermediate right ventricle.
Background: Stenting of the patent ductus arteriosus and radiofrequency valvotomy have been proposed as the
initial intervention for patients with intermediate right ventricle inasmuch as the sustainability for biventricular
circulation or 1½-ventricle repair is unclear in the early period.
Methods: Between January 2001 and April 2009, of 143 patients with pulmonary atresia and intact ventricular
septum, 37 who had bipartite right ventricle underwent radiofrequency valvotomy and stenting of the patent duc-
tus arteriosus as the initial procedure. The mean tricuspid valve z-score was3.8  2.2 and the mean tricuspid
valve/mitral valve ratio was 0.62  0.16.
Results:Median age was 10 days (3–65 days) and median weight 3.1 kg (2.4–4.9 kg). There was no procedural
mortality. Acute stent thrombosis developed in 1 patient and necessitated emergency systemic–pulmonary
shunt. There were 2 early in-hospital deaths owing to low cardiac output syndrome. One late death occurred ow-
ing to right ventricular failure after the operation. Survival after the initial procedure was 94% at 6 months and
91% at 5 years. At a median follow-up of 4 years (6 months to 8 years), 17 (48%) attained biventricular circu-
lation with or without other interventions and 9 (26%) achieved 1½-ventricle repair. The freedom from reinter-
vention was 80%, 68%, 58%, and 40% at 1, 2, 3, and 4 years, respectively.
Conclusions: Concomitant stenting of the patent ductus arteriosus at the time of radiofrequency valvotomy in
patients with pulmonary atresia with intact ventricular septum and intermediate right ventricle is feasible and
safe with encouraging medium-term outcome. (J Thorac Cardiovasc Surg 2011;141:1355-61)The wide anatomic spectrum of pulmonary atresia with in-
tact ventricular septum (PAIVS) is widely recognized and
thus management strategy needs to be tailored.1-3 Patients
with membranous atresia and well-developed, ‘‘tripartite’’
right ventricle (RV) generally respond well with
radiofrequency-assisted valvotomy and balloon dilatation
(RFV) or alternatively surgical valvotomy in the neonatal
period. Thismay be the only procedure required (2-ventricle
circulation).4 At the other end of the anatomic spectrum are
patients with severe RV hypoplasia, absent infundibulum
(muscular atresia), often associated with major RV–
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pulmonary shunt as the initial palliation.5 Of interest are
patients with intermediate anatomy in whom the atresia is
membranous and the infundibulum is fairly well developed
but the RV is moderately hypoplastic; often the RV is de-
scribed as ‘‘bipartite.’’ At presentation it is unclear whether
the RV would ultimately be able to independently support
the pulmonary circulation.6
Although RFV is effective in opening up the pulmonary
valve and decompressing the RV, a significant proportion
of patients, especially those with moderate RV hypoplasia,
require a systemic–pulmonary shunt within days of the pro-
cedure.7,8 The objectives of this study were to determine the
feasibility and safety of concomitant stenting of the patent
ductus arteriosus (PDA) at the time of RFV in the
subgroup of patients with intermediate RV and, second, to
review the medium-term outcome of this subgroup.
METHODS
Definition and Patient Selection
All patients with PAIVS underwent detailed echocardiography and
this served as the basis for the initial strategy, which consist mainly ofdiovascular Surgery c Volume 141, Number 6 1355
Abbreviations and Acronyms
ASD ¼ atrial septal defect
MV ¼ mitral valve
PAIVS ¼ pulmonary atresia with intact
ventricular septum
PDA ¼ patent ductus arteriosus
RV ¼ right ventricle
RVF ¼ radiofrequency-assisted valvotomy and
balloon dilatation
RVOT ¼ right ventricular outflow tract
TV ¼ tricuspid valve
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Dcatheter-based therapies. The tricuspid valve (TV) and mitral valve (MV)
diameters were measured in diastole. The TV z-score was derived from
the normogram by Rowlatt, Rimoldi, and Lev,9 and TV z-score was calcu-
lated.10 The RV cavity was also described as tripartite, bipartite, or unipar-
tite, depending on the number of parts of the RV (inlet, apical trabecular,
and outlet) not obliterated by intracavity muscular overgrowth. Particular
attention was paid to whether there was a well-formed infundibulum that
ended in a membranous atresia or was obliterated by muscles (muscular
atresia). TV regurgitation and its severity, if present, were noted as well
as RV–coronary communications. Patients with ‘‘good’’ RV are those
with a TV z-score of more than2.5, a TV/MV ratio of 0.75 or more,
and membranous atresia with a well-formed infundibulum in which the
RV cavity was described as tripartite. The RV volume was not measured
quantitatively.10 Patients with a ‘‘severely diminutive’’ RV were defined
as those having a TV z-score of less than5.0, a TV/MV ratio of less
than 0.5, and an RV cavity described as unipartite, in which only the inlet
component was present and the infundibulum was absent or slitlike. These
2 subgroups were excluded from the study. Also excluded were patients
with branch pulmonary artery stenosis, usually the left at the site of ductal
insertion. The subjects of this study, termed as having ‘‘intermediate’’ RV
morphology, were those with a TV z-score of2.5 to5.0 and/or a TV/MV
ratio of 0.50 to 0.75, with the RV described as ‘‘bipartite,’’ where apart from
the inlet component, a well-formed infundibulum ends in a membranous
atresia but the apical trabecular component is absent or attenuated. The de-
cision for recruitment into the study was made by a consensus of 2 of the
authors (M.A. and H.S.). Ethics committee approval was obtained.
RFV and PDA Stenting, Postprocedure Care
All patients were subjected to cardiac catheterization under general an-
esthesia with a view toward catheter-based intervention. Patients with
a good RV underwent RFV only. Patients with a severely diminutive
(unipartite) RV received PDA stenting only if the PDAwas suitable; other-
wise, they were referred for systemic–pulmonary shunt. The study patients,
those with an intermediate RV, received RFVand concomitant PDA stent-
ing. Prostaglandin E1 was discontinued the evening before the procedure to
ensure the PDA was restrictive. Informed consent was obtained. Baseline
hemodynamic data and oxygen saturation were obtained. RV angiogram
was performed to delineate the RV cavity, particularly the infundibulum,
the valve, and subvalvular area, and to document RV–coronary communi-
cations and the possibility of RV-dependent coronary circulation. RV
decompression with RFV was not performed in the presence of RV-
dependent coronary circulation. Aortic arch angiography was performed
to delineate the PDA and the pulmonary artery anatomy for the purpose
of PDA stenting. RFVand PDA stenting were performed using techniques
and equipment as we4,11 previously described. Coronary stents were used
and the sizes chosen were 3.5 mm for patients weighing 2.5 to 2.9 kg,
4.0 mm for those weighing 3.0 to 3.5 kg, and 4.5 mm for those weighing1356 The Journal of Thoracic and Cardiovascular Surmore than 3.5 kg. The stent length was according to that of the PDA. All
procedures were done by the transfemoral route. PDA stenting was not
performed if branch pulmonary artery stenosis at the site of ductal
insertion was shown by angiography. Early in the series, balloon atrial
septostomy was also performed if the patent foramen ovale was
restrictive, but this was subsequently omitted because we believed that
a large interatrial communication would reduce flow to the TV and
impair RV growth. After the procedure, the patients were returned to the
intensive care unit for continued ventilation and inotropic support as
necessary. Heparin infusion was given for 2 days and oral aspirin started
the following day and continued until the end point was reached.
Immediate Early Outcome, Follow-up, and
Subsequent Procedures
Patients were discharged from the intensive care unit if they could be
extubated, could maintain an oxygen saturation greater than 75% in air,
and could maintain stable hemodynamics without intropic support. Early
reintervention is defined as the patient requiring a systemic–pulmonary
shunt within 30 days of the procedure owing to oxygen saturation less
than 70% or requiring other surgical/catheter procedures.
After discharge, the patients were reviewed at 1 month, 3 months, and
then every 6 months. The degree of cyanosis was assessed clinically. The
major tool for evaluation was echocardiography, focusing on the growth
of the RV by measuring the TV and MV, and a general assessment of RV
cavity, in particular the apical trabecular component. Tricuspid regurgita-
tion, if present, was monitored as well as any residual or recurrence of val-
vular or subvalvular stenosis. The flow through the ductal stent was noted.
The end points were death before subsequent procedures and, for
the surviving patients, attainment of either 2-ventricle circulation or
1½-ventricle circulation. The patients were described as having 2-ventricle
circulation and no further treatment was deemed necessary if there was no
obvious clinical cyanosis, the echocardiographic evaluation fit the descrip-
tion of tripartite RV with a gradient of 40 mm Hg or less across the RVout-
flow tract (RVOT), absent or minimal flow through the PDA, and minimal
shunt through the patent foramen ovale. Significant additional problems,
if present, such as RVOT obstruction owing to subvalvular muscular
overgrowth or hypoplastic pulmonary annulus, shunts through the ASD
or PDA, and tricuspid regurgitation were addressed before being catego-
rized as having attained the 2-ventricle circulation.
Patients who remained cyanotic despite good antegrade flow and whose
RV growth remained inadequate after 36 to 60 months were subjected to
1½-ventricle circulation by having bidirectional cavopulmonary shunt.
Prior cardiac catheterization was performed partly to specifically look
for branch left pulmonary artery stenosis as a possible late complication
of PDA stenting. At the time of the bidirectional cavopulmonary procedure,
the ASD was closed, the PDA stent divided, and additional problems, if
present, such as TV regurgitation, RVOT obstruction, pulmonary annular
hypoplasia, and branch left pulmonary artery stenosis were addressed ac-
cordingly. Patients who had not reached either end point were considered
as ‘‘awaiting.’’
Analysis of Data
The SPSS statistical program for Windows, version 17.0 (SPSS, Inc,
Chicago, Ill), was used for data analysis. Data was expressed as mean 
SD, median (range), and frequency (percentage). Survival and freedom
from reinterventions were determined by the Kaplan–Meier method. Rein-
tervention was defined as either catheter-based intervention or surgery.RESULTS
Between January 2001 and April 2009, 143 patients
with PAIVS were referred to our institution. Forty-five
patients had good RV (tripartite) and underwent RFVonly.gery c June 2011
TABLE 1. Demographic, echocardiographic, periprocedural, and
follow-up data
Median age (d) 10 (3–65)
Median weight (kg) 3.1 (2.6–4.9)
Mean TV/MV ratio 0.62  0.16
Mean z-score of TV annulus 3.8  2.2
Mean procedure time (min) 111  39
Median ventilation days (d) 1 (1–15)
Median length of hospital stay (d) 8 (4–23)
Median follow up (y) 4 (½–8.2)
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and received PDA stenting only. Thirty-seven patients,
who formed the subjects of this study (ie, intermediate RV
size [bipartite]), received RFV and elective PDA stenting
as the initial procedure. Early in the series, 8 (22%) patients
received additional balloon atrial septostomy.
The median age at procedure was 10 days (3–65 days)
and the mean weight was 3.1 kg (2.6–4.9 kg). The TV
z-score was 3.8  2.2. The TV/MV ratio was 0.62 
0.16 (Table 1).
In all patients the RV cavity was described as bipartite,
having definite inlet and infundibular components with
membranous atresia, whereas the apical trabecular compo-
nent was severely attenuated. Moderate-to-severe tricuspid
regurgitation was present in 12 (32%) patients. Major sinu-
soids were present in 3 (8.1%), but none had RV-dependent
coronary circulation.
The mean procedural time was 111  39 minutes.
The median duration of ventilatory support was 1 day
(1–15 days). The median length of hospital stay was 8 days
(4–23 days) (Table 1).FIGURE 1. Outcome of patients with intermediate right ventricle (RV). BT, Bl
flow tract; PTBV, percutaneous transcatheter balloon valvuloplasty; PDA, paten
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There was no procedural mortality. Two (5%) patients
had transient supraventricular tachycardia. One patient
had acute stent thrombosis within 24 hours, necessitating
systemic–pulmonary shunt. Loss of femoral arterial pulse
occurred in 5 (14%) and was successfully treated with hep-
arin and streptokinase.
There were 2 early in-hospital deaths owing to low car-
diac output at 10 and 12 days after the procedure. One of
these patients had major sinusoids and the other had pulmo-
nary overcirculation. One late death was due to RV failure
after RVOT reconstruction surgery. Survival after the initial
procedure was 94% at 6 months and remained at 91% from
1 to 4 years (Figure 1).
Follow-up
At a median follow-up of 4 years (6 months to 8.2 years),
8 (23%) patients had not reached the study end point
(follow-up <24 months; ie, ‘‘awaiting’’). Seventeen
(48%) attained biventricular circulation, 8 of whom re-
quired reinterventions: transcatheter closure of ASD
(n ¼ 2), repeat balloon pulmonary valvuloplasty (n ¼ 1),
surgical RVOT reconstruction (n ¼ 4), and PDA restenting
and balloon pulmonary valvuloplasty at 3 months, followed
by RVOT reconstruction at 14 months (n ¼ 1). Nine (26%)
patients did not achieve sufficient RV growth and received
bidirectional cavopulmonary shunt, ASD closure, and
PDA stent division (1½-ventricle repair), of whom
3 (33%) also received RVOT reconstruction (Figure 1).
No patient had left pulmonary artery stenosis.
The freedom from reintervention was 80%, 68%, 58%,
and 40% at 1, 2, 3, and 4 years, respectively (Figure 2).alock–Taussig shunt; ASD, atrial septal defect; RVOT, right ventricular out-
t ductus arteriosus.
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FIGURE 2. Freedom from reintervention (overall).
FIGURE 3. Freedom from reintervention (biventricular circulation).
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the freedom from reintervention was 77%, 70%, 70%,
and 61% at 1, 2, 3, and 4 years, respectively (Figure 3).
The mean TV score at presentation for thosewho attained
biventricular circulation and 1½-ventricle repair was2.8
1.8 and4.1  2.3, respectively.
DISCUSSION
The wide variation of RV morphology in PAIVS has long
been recognized and management algorithms have largely
been based on this.1-3 At one end of the morphologic
spectrum are those with a good RV in whom the 3
components of the RV cavity are reasonably well
developed—the inlet, apical trabecular, and outlet or
infundibulum—even if the RV in general is smaller than
that of the normal population. The atresia in this group of
patients is membranous in nature. This is the group with
the most favorable outcome, comprising 50% to 60% of
patients. RV decompression and establishing unobstructed
antegrade flow into the pulmonary circulation by surgical
valvotomy or RFV in the neonatal period is often the only
procedure required, the latter being the favored method of
treatment today.4
At the other end are those with severely diminutive RV
with obliteration of the apical trabecular and infundibular
cavity. These patients are inevitably destined for the Fontan
track.3,5,12 Inasmuch as they are ductus dependent, an initial
palliation with systemic–pulmonary shunt is required. PDA
stenting, being less invasive, is an attractive alternative to
surgical shunt. This is particularly suited to PAIVS, in
which the ductus tends to be more amenable to stenting
compared with other forms of cyanotic heart disease.11,13,14
This is our preferred mode of initial management.
However, a significant proportion of patients do not ex-
hibit RV features that clearly suggest either the favorable1358 The Journal of Thoracic and Cardiovascular Sur2-ventricle eventual outcome or the less favorable single-
ventricle pathway. In our algorithm, this subgroup of pa-
tients was designated ‘‘intermediate.’’6 The characteristic
features on echocardiography that define this subgroup
are TV z-score 2.5 to 5.0, MV/TV ratio 0.5 to 0.75,
and an RV cavity that has a severely attenuated apical tra-
becular component but with a reasonably well-developed
infundibulum that ends with a membranous valvular atresia,
‘‘bipartite RV.’’
Somewhat out of this continuum of RV morphology are
the rare patientswith Ebstein anomaly, who have amarkedly
dilated, thin-walled, poorly functioning RV with severe tri-
cuspid regurgitation.2 Even today the outlook is very poor,
with or without intervention.
Catheter-based therapies have markedly altered the man-
agement of PAIVS. RFV is currently the preferred method
of initial management, achieving results comparable with
if not superior to conventional surgery.4,7,8 The PDA in
this condition tends to arise obtusely from the descending
aorta to insert onto the dome of the main pulmonary
artery rather than onto the proximal left pulmonary artery,
making PDA stenting an attractive alternative to
systemic–pulmonary shunt. Transcatheter device closure
of shunts at ASD or PDA levels can be done as the final
procedure. Radical surgery, such as RVOT reconstruction
in the neonatal period, is associated with high mortality
and morbidity.12 However, surgery remains an important
part of management of PAIVS, especially for those with
severely diminutive RV who require the Fontan opera-
tion.5,12,15,16 In patients with intermediate RV that
remains incapable of independently supporting the
pulmonary circulation, the bidirectional cavopulmonary
shunt is an integral part of the 1½-ventricle repair.17-19
Although data are currently lacking, we are of the opinion
that in the long term the 1½-ventricle circulation isgery c June 2011
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major late complications of the Fontan operation are
attributed to the absence of pulsatile flow. This is our
basis for this management strategy for those with
borderline, ‘‘intermediate’’ RV. Surgery may also be
additionally required in patients with fixed RVOT
obstruction and severe tricuspid regurgitation in both the
2-ventricle and 1½-ventricle pathways.
Less Ideal RV Size and the Basis for ‘‘Prophylactic’’
PDA Stenting
The focus of our interest is on the subgroup of patients
with borderline or ‘‘intermediate’’ RV, one that is difficult
to determine at the time of presentation whether it would
eventually be capable of sustaining the pulmonary circula-
tion (2-ventricle) or have to be supported by a bidirectional
cavopulmonary shunt (1½-ventricle). The initial manage-
ment of patients with intermediate RV as defined herein is
somewhat less clear-cut than those with good tripartite
RVor those with severely diminutive RV.
In the surgical era, closed valvotomy or transannular
patch with concomitant systemic–pulmonary shunt is a pop-
ular management strategy for all patients with patent infun-
dibulum.20,21 It was not uncommon for patients to require
such a shunt within days of surgical valvotomy alone
owing to unacceptably low arterial oxygen tension, hence
the concept of ‘‘prophylactic’’ systemic–pulmonary shunt
at the time of valvotomy. A parallel situation was
encountered in the era of transcatheter management with
RFV. In a relatively large series of PAIVS patients with
seemingly good RV (mean TV z-score 1.33), 14 of 27
patients who successfully underwent RFV required the
construction of a systemic–pulmonary shunt 2 to 24 days
after the initial procedure.8 At about the same time, Agno-
letti and associates7 reported that after successful perfora-
tion in 33 patients (medium TV z-score1.2), 12 required
a Blalock–Taussig shunt and 8 required a Blalock–Taussig
shunt and RVOT reconstruction 1 to 30 days after the initial
procedure, with a bias toward those with more negative TV
z-score requiring early surgical reintervention. This was
also reflected in our own experience, although the propor-
tion of patients who required systemic–pulmonary shunt
or PDA stenting within 14 days of RFV was lower.22 On
the basis of these findings, in patients who are identified
as having less ideal RV size, that is, the intermediate RV
group, there is merit in incorporating PDA stenting into
RFV as initial management. The rationale is to avoid rein-
tervention, either systemic–pulmonary shunt or PDA stent-
ing, within days of RFV by maintaining the PDA as an
additional source of pulmonary flow until there is sufficient
RV ‘‘growth’’ (2-ventricle) or otherwise where there is
a need then for bidirectional cavopulmonary shunt
(1½-ventricle). That PDA stenting in the current era has
shown results that are comparable with those of Blalock–The Journal of Thoracic and CarTaussig shunt in terms of safety and efficacy provides fur-
ther rationale for this strategy.11,13,14 On the basis of data
from these 3 relatively large series and established
surgical practice, the argument for concomitant PDA
stenting in all patients with PAIVS undergoing RFV does
seem persuasive. However, PDA stenting as an alternative
to systemic–pulmonary shunt is a newly introduced
procedure, it is technically demanding, experience is
limited, and the full extent of its late complications is yet
to be known. Hence, this treatment strategy cannot be
universally recommended for all PAIVS patients, but
applying it for a selected group is justifiable.
Our results for this selected group of PAIVS patients
showed that this combined procedure was well tolerated
and the immediate outcome encouraging as reflected in
the intensive care unit stay. There were no deaths or major
acute complications owing to the PDA stenting itself, ex-
cept that in 1 patient acute stent thrombosis developed
within 24 hours, requiring emergency systemic–pulmonary
shunt.
From our experience, PDA stenting is a reasonable alter-
native to the Blalock–Taussig shunt in a selected group of
patients. However, one needs to be mindful of the possible
complications, such as acute stent thrombosis, aggressive
neointimal proliferation causing early stent flow restriction,
and late branch pulmonary artery stenosis in those in whom
the ductus is inserted at the left pulmonary artery. Hence,
this has to be excluded at the initial evaluation.11 In PAIVS,
RFV and PDA stenting may cause overcirculation and
myocardial ischemia, in particular in those with coronary
sinusoids.
In this series, major late complications of PDA stenting
were not encountered and a stented PDA did not pose a ma-
jor surgical challenge at the time of bidirectional cavopul-
monary shunt, where the stent was crushed, sutured with
5–0 Prolene polypropylene (Ethicon, Inc, Somerville, NJ),
and divided.
As anticipated, not all patients attained 2-ventricle circu-
lation, where normal oxygen saturation is achieved with the
RV supporting the entire pulmonary circulation and all
shunts abolished. It was also not surprising that 50% of pa-
tients who did attain the 2-ventricle end point required rein-
terventions in the form of RVOT reconstruction, ASD
closure, and TV repair given that they started off with less
ideal morphology. Twenty-six percent of patients did not
achieve sufficient RV ‘‘growth’’ after 3.7 years  2.9 years
and received bidirectional cavopulmonary shunt, ASD
closure, and PDA stent division (1½-ventricle repair).
RV ‘‘Growth’’
The potential for growth of the RV after decompression
and establishment of forward flow is difficult to predict.
There have been many published series documenting ana-
tomic growth of the RV, in part contributed by pulmonarydiovascular Surgery c Volume 141, Number 6 1359
FIGURE 4. A, Right ventricular (RV) handshot showing bipartite RV with fairly well-developed infundibulum with membranous atresia (thick arrow) and
inlet component (thin arrow).Muscle-bound apical trabecular component of RV is the area within dotted lines. Except for the intertrabecular recesses, the
cavity is virtually obliterated. Membranous atresia seen. RV/aortic pressures ¼ 153:73 mm Hg. B, RVangiogram after radiofrequency valvotomy and bal-
loon dilatation. Transient reactive spasm reduces RVoutflow tract cavity. C, Patent ductus arteriosus crossed with a balloon-mounted coronary stent retro-
gradely. D, Stent expanded and covering the full length of the patent ductus arteriosus. E, RVangiogram 4 years after radiofrequency-assisted valvotomy and
PDA stenting showing a well developed RV, unobstructed pulmonary blood flow, no branch pulmonary artery stenosis, and regression of muscular over-
growth resulting in a well-formed cavity of apical component of RV. Excellent overall growth of RV; ‘‘tripartite’’ end state. The patent ductus arteriosus
stent is hardly visible.
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hypertrophy after RV decompression.20,23,24 This is also
illustrated by 1 of our patients (Figure 4, A–E). On the other
hand, there seem at times, overly optimistic expectations on
the capacity for the RV to grow inasmuch as there are also
data that showed no significant catch-up anatomic growth of
the TV. However, even if there is no catch-up growth, some1360 The Journal of Thoracic and Cardiovascular Surpatients were still able to attain 2-ventricle circulation de-
spite the subnormal RV size.8,25 It is thus difficult to
determine the size of the RV that will contribute to
a successful 2-ventricle circulation. It appears that normal
TV growth is not mandatory to have an RV capable of
sustaining the pulmonary circulation. ‘‘Physiologic’’
growth, that is, improved compliance, is of greater importgery c June 2011
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decompression provides the opportunity for the RV to attain
its maximal potential for ‘‘growth,’’ both anatomic and
physiologic. This can be done less invasively by RFV, and
PDA stenting helps support the pulmonary circulation in
the interim until either of the end points is reached.
CONCLUSIONS
Concomitant PDA stenting at the time of RFV in PAIVS
patients with intermediate RV size is feasible and safe. This
treatment strategy largely obviated the need for emergency
procedures to augment pulmonary blood flow although
acute stent thrombosis may occur in a small percentage.
A quarter of patients with intermediate RVeventually re-
quired bidirectional cavopulmonary shunt (1½-ventricle),
whereas among those who attained biventricular circula-
tion, a significant proportion required additional proce-
dures. Concomitant with RFV, PDA stenting should be
considered an integral part of the initial management in
PAIVS with intermediate RV. However, inasmuch as PDA
stenting is a relatively new procedure and PAIVS is an un-
common disease, this management strategy warrants wider,
multi-institutional study.
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